Global pharma set for strong year

23 Oct 2018

Eight of the top ten pharma nations reporting improving market conditions.

CPhI Worldwide closes its 29th edition with pre-audit figures showing the most international audience in the event’s history, with a total unique attendance of 44,500 – over 39,000 of which were international.

Global pharma set for strong year

This year’s event highlighted a number of new trends across the industry and collectively with bioLIVE – the bioprocessing and manufacturing exhibition added in 2018 – played host to more than 150+ sessions. Held at the IFEMA center in Madrid (October 9-11), attendees came from a record 164 countries, with 47% at C-level or above.

The standout new addition at this year’s event and one of the biggest overall trends to emerge is the integration of small and large molecules – with bioLIVE bringing the biologics supply chain into the wider CPhI family. Sessions here highlighted the developments in ‘cell and gene therapies’, ‘biosimilars’ and ‘capacity challenges in Europe, the US and Asia’, as well as new manufacturing and processing techniques – spanning 45 hours of insights over 3 days.

CPhI Worldwide is widely used as a barometer of pharma’s overall health – as the only platform that brings together global pharma – and a strong event is reflective of a prosperous pharma sector. The industry looks set for an extremely strong 2019, as CPhI Worldwide received more than 103,000 visits over 3 days.

Emphasizing the strength of global pharma over the past year, in the annual survey conducted for CPhI Worldwide (CPhI Pharma Index), eight of ten top nations improved their overall score across all categories – with table topping nations the USA and Germany the only countries not to improve. In fact, for the second year running Germany, Japan and the US emerged as the top-ranked, tier-one nations for pharmaceutical quality and overall score – with India and China making dramatic strides in raising their overall reputations. Host nation of CPhI Worldwide 2018, Spain, also made a significant improvement with international perception of ‘innovation emerging in the country’ rising – driven notably by the biotech hubs in both Barcelona and Madrid. Most promising, however, was the improvement in growth potential industry-wide, as eight out of ten countries’ scores rose – with only Spain and China marginally lower than in 2017.

Since the last CPhI Worldwide was held in Madrid (2015), the industry has grown extremely quickly with attendee numbers increasing by 9,000 to nearly 44,500. Attendees from the world’s largest pharma economy also continue to grow, with visitors from the US increasing by 8% in the last year, as well as an impressive 27% rise from South America.

The organiser attributes this year’s stellar event to its bespoke customer focus as well as the wider market conditions in pharma. Orhan Caglayan, Brand Director added: “The 2018 CPhI Worldwide event showcased the incredible strength of pharma, and we are seeing good growth potential across all sectors from API and finished product to bio, generics and NCEs. But what has been most significant is the internationalization of partnering; furthermore, we see a wider spread of international attendees year-on-year at CPhI Worldwide. Another notable trend and reflected in our content programmes at the event, has been the rise of innovation in the industry, with more new products in development, but also, new technologies that lower overall production costs.

In total, CPhI Worldwide – along with bioLIVE, ICSE, FDF P-MEC, and Innopack – featured 22 country pavilions and 19 different zones covering the entire supply chain. Finally, 4,300+ attendees viewed the sessions available throughout the event, which included a who’s who of prominent executives and experts exploring the future of the industry. The agenda included keynote speeches on ‘quality by design’, ‘introduction and implementation of continuous manufacturing’, ‘smart-packaging’, and the ‘digital future of pharma’ to name just a few.

Read More

Related news

'Tamper-evident' benefits are evident

'Tamper-evident' benefits are evident

28 Feb 2019

2019 will mark Uniplast's debut at this year's edition of CPhI Worlwide in Frankfurt, where it will showcase its expertise in plastic packaging.

Read more 
All Recipharm facilities ready for EU serialisation, regardless of Brexit

All Recipharm facilities ready for EU serialisation, regardless of Brexit

15 Feb 2019

The CDMO invested EUR 35 million into its operations and launched a 3-year programme to provide a compliant serialisation solution for its customers.

Read more 
Brexit - the EU FMD's painful problem

Brexit - the EU FMD's painful problem

7 Feb 2019

Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.

Read more 
Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

27 Jan 2019

New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.

Read more 
New API screening program strengthens Particle Sciences' nanomilling offering

New API screening program strengthens Particle Sciences' nanomilling offering

22 Jan 2019

Advanced formulation techniques such as nanomilling may provide an excellent route to improved bioavailability and enhanced therapeutic effect.

Read more 
Univercells introduces breakthrough vaccine manufacturing platform

Univercells introduces breakthrough vaccine manufacturing platform

13 Jan 2019

The automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint.

Read more 
BMS and Celgene merge to create premier innovative biopharma company

BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Read more 
An increased risk of a hard or ‘no deal Brexit?

An increased risk of a hard or ‘no deal Brexit?

24 Dec 2018

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Read more 
One month on: medical cannabis is still taboo despite change in law

One month on: medical cannabis is still taboo despite change in law

11 Dec 2018

Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.

Read more 
EU FMD - time is running out!

EU FMD - time is running out!

13 Nov 2018

Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.

Read more